Zoetis Inc. ZTS
Zoetis Inc. (NYSE: ZTS) is an animal health company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Oct 31, 2026approval Zoetis received U.S. FDA approval for Convenia RTU for Dogs, a long-acting antibacterial injection for dogs, with availability expected in Q1 2027.
In October, Zoetis received U.S. Food and Drug Administration (FDA) approval for Convenia® RTU for Dogs, a long-acting antibacterial injection for dogs.
Filing - Sep 30, 2026approval Simparica Trio received U.S. FDA Emergency Use Authorization for treatment of New World screwworm infestations in dogs and puppies.
During the quarter, Simparica Trio® received U.S. FDA Emergency Use Authorization (EUA) for the treatment of New World screwworm infestations in dogs and puppies.
Filing - Sep 30, 2026approval Fostera PRRS Needle-free microdose was approved in the U.S. and Mexico to help protect pigs against porcine reproductive and respiratory syndrome.
Fostera® PRRS Needle-free microdose was approved in the U.S. and Mexico to help protect pigs against porcine reproductive and respiratory syndrome.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.